Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
Novartis has withdrawn its EU application for radioligand therapy Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain favor with the European ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CH
- [DIPLOMACY] Key Go-Between Switzerland to Reopen Embassy in Iran
- [CONFLICT] İsviçre, güvenlik gerekçesiyle kapattığı Tahran Büyükelçiliğini yeniden açmak için hazırlık yapıyor
- [FINANCE] SNB Chief Economist Lenz to Retire, With Brown Set to Take Over
- [FINANCE] Finma Says Immediate Mythos Access Would Pose Systemic Bank Risk
- [FINANCE] Swiss central bank has no plans to increase gold reserves, says chairman - Mining.com
- [AVIATION] Noida International Airport Appoints Nitu Sarma As Interim Chief